4-MUST; Placebo
Проводит Valenta Pharm JSC
Страница компанииMulticenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07595003/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 300 чел. во всех странах исследования.
- Центров в реестре: 9 в 5 городах. Список — ниже на странице.
- Плановое окончание — 12.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 45 · невключение: 12
Критерии включения
- Males and females aged 18-70 years.
- Diagnosed with chronic cholecystitis (K81.1) and/or dyskinesia of the cystic duct or gallbladder (K82.8) prior to enrollment; diagnosis supported by clinical history of exacerbations and remissions and/or imaging/laboratory findings.
- Upper abdominal pain or discomfort attributable to gallbladder or biliary tract dysfunction (per investigator assessment), accompanied by ≥1 of the following: heartburn, belching, nausea, abdominal bloating, borborygmi (stomach rumbling), flatulence, constipation, or diarrhea.
- Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
- Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
- The total bilirubin level does not exceed 2 times the upper limit of normal (no more than 42 μmol/L).
- Women who are either sexually abstinent or using effective contraception methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
- Signed and dated informed consent from.
- Non-inclusion Criteria:
- Gastric or duodenal ulcer, erosive gastroesophageal reflux disease (GERD), or other inflammatory/erosive gastrointestinal diseases in the acute stage, unless stable remission for ≥ 1 year since the last exacerbation.
- Indication for surgical or endoscopic intervention due to exacerbation of chronic cholecystitis or complications of biliary tract dyskinesia.
- Toxic megacolon.
- Paralytic ileus.
- Gilbert's syndrome.
- Choledocholithiasis (or a high risk of its development, as determined by the investigator);
- Impaired bile outflow due to adhesions in the abdominal cavity.Abdominal adhesion disease.
- Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
- Gastrointestinal malignancy (including history of) or suspected gastrointestinal malignancy (e.g., blood in stool, unexplained weight loss, fever, anemia).
- Any other oncological diseases known at the time of screening, or suspicion thereof.
- History of gastrointestinal surgery, including cholecystectomy or endoscopic sphincterotomy (appendectomy excluded).
- Use of prohibited therapy medications within 3 days prior to randomization.
- History of mental illnesses.
- Chronic heart failure IIb-III stages and/or III-IV functional classes according to NYHA, angina pectoris III-IV functional classes.
- Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
- History of or current hepatic impairment; or liver test abnormalities: AST, ALT, ALP, or GGT >3 above the upper limit of normal (ULN); total bilirubin >2 ULN or clinical jaundice.
- HIV, syphilis, viral hepatitis B or C, including in history.
- Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
- Liver cirrhosis.
- Hypersensitivity to the active ingridient or any of the excipients of the drug 4-MUST.
- Severe, decompensated, or unstable somatic conditions that are life-threatening, worsen prognosis, or preclude safe study participation.
- Diabetes mellitus in a state of subcompensation and decompensation.
- Systemic connective tissue diseases.
- Autoimmune diseases.
- Indication for hemodialysis procedures.
- Epilepsy or seizures of unclear etiology, including in history.
- Alcoholism, substance abuse or drug addiction, including in history.
- Uncorrected electrolyte disturbances.
- QTcF interval on a 12-lead electrocardiogram (ECG) ≥430 ms in men and ≥450 ms in women.
- Episodes of constipation during the last 3 months that required the prescription of drug therapy.
- History of surgery within 6 month prior to screening.
- Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
- Patients who require prohibited concomitant therapy within this study framework.
- Participation in another clinical trial within the last 3 months prior to the screening visit date.
- Unwillingness or inability to comply with study procedures and protocol requirements..
- Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.
Критерии невключения
- Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
- Lack of Efficacy. Study treatment will be discontinued if no clinical improvement is observed by Visit 3 (Day 15 ± 1), defined as persistence or worsening of upper abdominal pain/discomfort (assessed by Visual Analog Scale \[VAS\]) compared to baseline. Upon discontinuation, alternative therapy will be initiated at the investigator's discretion.
- Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
- Requirement for prohibited concomitant therapy.
- Use of Duspatalin® (INN: mebeverine) for more than 3 consecutive days or for more than 5 days in total throughout the study.
- If the investigator judges that comtinued participation in the study would harm the patient.
- Pregnancy or the need for breastfeeding.
- Major protocol deviation by the subject with respect to procedures outlined in the Informed Consent Form (ICF).
- Withdrawal of informed consent by the subject (decision to discontinue study participation).
- Lost to follow-up: Inability to contact the subject after ≥3 documented attempts via mobile phone, landline (if applicable), and designated emergency contact.
- Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
- Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.
Источник: ClinicalTrials.gov, NCT07595003 · запись обновлена в реестре 19 мая 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 65
- Mean reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline — Day 29 ± 1
Цель исследования
The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.
Где проходит
9 центров в 5 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07595003 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.